하인두암의 치료방법에서 Docetaxel과 Platinum을 이용한 선행항암화학요법의 효과분석

김종승; 이경석; 황병언; 임상호; 유순호; 하일우; 이은정; 홍기환; 양윤수

추천

검색

자료유형: 학술저널

저자정보: 김종승 이경석 황병언 임상호 유순호 하일우 이은정 홍기환 양윤수

저널정보: 대한이비인후과학회 대한이비인후-두경부외과학회지 대한이비인후과학회지 두경부외과학 제53권 제11호

발행연도: 2010.1

수록면: 706 - 711 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background and Objectives The aim of this study was to determine the efficacy of induction chemotherapy with docetaxel and platinum in patients with hypopharyngeal carcinoma. Subjects and Method The medical records of 66 patients who were diagnosed with hypopharyngeal carcinoma at our department from January 1996 to December 2008 were reviewed and retrospectively analyzed. The patients were divided into four groups according to treatment method: Group I was treated with radiation and induction chemotherapy consist of docetaxel and platinum (27); Group II was treated with surgery and induction chemotherapy consist of docetaxel and platinum (28), Group III was treated with radiation and induction chemotherapy consist of 5-FU and platinum (9) and Group IV was treated with surgery and induction chemotherapy consist of 5-FU and platinum (2). A total of 186 chemotherapy cycles were administered to patients and most of the patients received at least 2 cycles. Results The T-stage distribution at diagnosis was 7.5%, 42.4%, 28.8%, and 21.2% for T1, T2, T3, and T4, respectively. The N-stage distribution at diagnosis was 48.5%, 22.7%, 10.6%, 15.2%, and 9.1% for N0, N1, N2a, N2b, and N2c, respectively. The overall 3-year survival rate was 44.3%. The 3-year survival rate of each group was 42.6% in Group I, 54.8% in Group II, and 11.1% in Group III. There was no significant difference in survival between Groups I and III (p=0.074). There was no difference in sex, age, and N stage for 3-year survival rate. Conclusion Although any valid conclusions could not be drawn because of the small number of patients examined here, induction chemotherapy consisting of docetaxel and platinum may improve the outcome of patients with hypopharyngeal carcinoma. Korean J Otorhinolaryngol-Head Neck Surg 2010;53:706-11

#Hyppharyngeal carcinoma ㆍChemotherapy ㆍTreatment outcome.

참고문헌 (19)

참고문헌 신청

Catimel G / 1994 / Docetaxel (Taxotere): an active drug for the treatment of pa-tients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trial

Colevas AD / 2002 / Phase I-II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (op TPFL) as induction for squamous cell carcinoma of the head and neck (S

Cooper JS / 2000 / Concurrent chemotherapy and radiation therapy for advanced stage carcinoma of the nasopharynx / Int J Radiat Oncol Biol Phys 48 (5) : 1277 ~ 1279

Forastier AA / 1993 / Use of paclitaxel (Taxol) in squamous cell carcinoma of the head and neck / Semin Oncol 20 (4) : 56 ~ 60

Gourin CG / 2004 / Carcinoma of the hypopharynx / Surg Oncol Clin N Am 13 (1) : 81 ~ 98

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!